NASDAQ:ROIV Roivant Sciences (ROIV) Stock Forecast, Price & News $9.75 0.00 (0.00%) (As of 05:21 PM ET) Add Compare Share Share Today's Range$9.64▼$9.8550-Day Range$7.09▼$9.7552-Week Range$2.87▼$10.00Volume3.92 million shsAverage Volume2.87 million shsMarket Capitalization$7.39 billionP/E RatioN/ADividend YieldN/APrice Target$12.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Roivant Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside31.8% Upside$12.80 Price TargetShort InterestBearish3.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$100.32 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.78) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector366th out of 982 stocksPharmaceutical Preparations Industry175th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.80, Roivant Sciences has a forecasted upside of 31.8% from its current price of $9.71.Amount of Analyst CoverageRoivant Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.50% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Roivant Sciences has recently increased by 2.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 2.9 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Roivant Sciences this week, compared to 3 articles on an average week.Search Interest13 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,320,605.00 in company stock.Percentage Held by Insiders13.00% of the stock of Roivant Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.66% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.78) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Roivant Sciences (NASDAQ:ROIV) StockRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Read More Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Stock News HeadlinesMay 27, 2023 | msn.comRoivant Sciences: Coming Nicely To The Boil With Multiple OpportunitiesMay 22, 2023 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) PT Raised to $14.00 at JPMorgan Chase & Co.June 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 19, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Roivant Sciences (ROIV)May 18, 2023 | msn.comJP Morgan Maintains Roivant Sciences (ROIV) Overweight RecommendationMay 17, 2023 | msn.comHC Wainwright & Co. Maintains Roivant Sciences (ROIV) Buy RecommendationMay 17, 2023 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Price Target Raised to $15.00 at HC WainwrightMay 17, 2023 | barrons.comS&P 500 Futures Rise in Premarket Trading; Roivant Sciences, Dynatrace LeadJune 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 17, 2023 | markets.businessinsider.comRoivant Sciences (ROIV) Receives a Buy from H.C. WainwrightMay 16, 2023 | msn.comMarching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 SubmissionMay 16, 2023 | msn.comRoivant stock rises after Vtama meets main goal of 2nd phase 3 eczema studyMay 16, 2023 | finance.yahoo.comRoivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years OldMay 15, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Roivant Sciences (ROIV)May 12, 2023 | yahoo.comOhio presidential candidate says U.S. should raise voting age from 18 to 25May 12, 2023 | msn.comHC Wainwright & Co. Reiterates Roivant Sciences (ROIV) Buy RecommendationMay 12, 2023 | markets.businessinsider.comRoivant Sciences (ROIV) Gets a Buy from H.C. WainwrightMay 11, 2023 | bizjournals.comThe Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partnerMay 11, 2023 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $546,569.58 in StockMay 10, 2023 | americanbankingnews.comEric Venker Sells 88,838 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockMay 6, 2023 | americanbankingnews.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells $130,653.14 in StockMay 4, 2023 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 109,074 SharesMay 1, 2023 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $625,604.14 in StockMay 1, 2023 | americanbankingnews.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells $762,364.40 in StockApril 29, 2023 | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) CAO Rakhi Kumar Sells 71,989 SharesApril 24, 2023 | barrons.comS&P 500 Futures Fall in Premarket Trading; Roivant Sciences, DoubleVerify LeadApril 20, 2023 | msn.comThese 2 Growth Stocks Might Be Incredibly Undervalued Right NowSee More Headlines ROIV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Company Calendar Today6/07/2023Next Earnings (Estimated)6/27/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees620Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.80 High Stock Price Forecast$15.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+31.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-845,260,000.00 Net Margins-2,887.92% Pretax Margin-3,100.36% Return on Equity-73.96% Return on Assets-51.87% Debt Debt-to-Equity Ratio0.26 Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$55.29 million Price / Sales134.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book3.33Miscellaneous Outstanding Shares758,430,000Free Float659,831,000Market Cap$7.41 billion OptionableNot Optionable Beta1.22 Key ExecutivesMr. Vivek Ramaswamy (Age 37)Founder & Chairman Comp: $1.26MMr. Matthew Gline (Age 38)CEO & Director Comp: $1.45MDr. Eric Venker M.D. (Age 35)Pharm.D., Pres & COO Comp: $981.38kDr. Mayukh Sukhatme M.D. (Age 46)Pres & Chief Investment Officer Comp: $910.19kMr. Richard Pulik (Age 43)Chief Financial Officer Ms. Rakhi Kumar (Age 42)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Josh ChenGen. CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 54)Head of Global Transactions & Risk Management More ExecutivesKey CompetitorsCatalentNYSE:CTLTTeva Pharmaceutical IndustriesNYSE:TEVAJazz PharmaceuticalsNASDAQ:JAZZIntra-Cellular TherapiesNASDAQ:ITCIIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 19,700 shares on 6/1/2023Ownership: 0.005%ProShare Advisors LLCSold 7,416 shares on 5/26/2023Ownership: 0.007%Eric VenkerSold 415 sharesTotal: $4,087.75 ($9.85/share)JPMorgan Chase & Co.Bought 266,464 shares on 5/18/2023Ownership: 0.045%New York State Common Retirement FundBought 12,171 shares on 5/18/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ROIV Stock - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price forecast for 2023? 5 brokerages have issued 1-year target prices for Roivant Sciences' stock. Their ROIV share price forecasts range from $10.00 to $15.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2023? Roivant Sciences' stock was trading at $7.99 at the start of the year. Since then, ROIV stock has increased by 22.3% and is now trading at $9.77. View the best growth stocks for 2023 here. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 27th 2023. View our ROIV earnings forecast. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA Momentum ETF (PDP), Invesco Nasdaq Biotechnology ETF (IBBQ) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What is Roivant Sciences' stock symbol? Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV." Who are Roivant Sciences' major shareholders? Roivant Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include SB Investment Advisers UK Ltd. (10.95%), FMR LLC (4.06%), Wellington Management Group LLP (1.59%), State Street Corp (1.06%), BlackRock Inc. (0.82%) and Rubric Capital Management LP (0.74%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Roivant Sciences' stock price today? One share of ROIV stock can currently be purchased for approximately $9.77. How much money does Roivant Sciences make? Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $7.41 billion and generates $55.29 million in revenue each year. The company earns $-845,260,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. How many employees does Roivant Sciences have? The company employs 620 workers across the globe. How can I contact Roivant Sciences? Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347. This page (NASDAQ:ROIV) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.